Australia-China Biotech Invest 2017, page-15

Hey Tech,

Redbar is correct, at this time they are only testing children. If they were including adults, I have no doubt they would have informed the market, as this would be price sensitive information.

However, as per the ann on the 10th of Jan: (my bold)

"ResApp Health Limited (ASX: RAP), the developer of smartphone medical applications for the diagnosis and management of respiratory disease, today announced that it has entered into a two-year expanded research collaboration with Massachusetts General Hospital (MGH) alongside MGH’s participation in ResApp’s SMARTCOUGH-C study. Working together, ResApp and MGH will perform additional analysis of the SMARTCOUGH-C study data, use the SMARTCOUGH-C dataset to investigate the state of respiratory disease clinical practice today and evaluate the efficacy of ResApp’s cough-based diagnostic test in additional respiratory disease indications."

I have absolute no doubt that plans are well underway to begin new studies relating to other respiratory illnesses.

What we also know from the above extract, is that any new pediatric study, will require smaller samples. All of the data collected in this SMARTCOUGH-C study, will also be analysed to see if it has diagnosed other conditions correctly.

Assume that only half the enrolled patients actually have pneumonia, then roughly 555 don't. This means that 555 had a different condition, and if RAP correctly diagnoses these, then any further study relating to these conditions will immediately begin with a large number of trials already completed.

Suffice to say, this means that every study conducted from now on, will require less and less enrollments. If the App is successful, for these other conditions, then FDA approvals will flow steadily.

The same will hold true for adult trials. We can assume the first lot to take 3 - 5 months, then from there as they expand their studies to include other conditions, smaller enrollment numbers will be required.